Eurocine Vaccines initiates process development of the vaccine candidate against chlamydia
Today, Eurocine Vaccines AB (“Eurocine Vaccines”) announces the completion of knowledge transfer and preparations for the development of the manufacturing process to secure the active…
Eurocine Vaccines confirms good immunological effect in preclinical study with the chlamydia vaccine candidate
Eurocine Vaccines AB (“Eurocine Vaccines”) confirms good immunological effect in a preclinical animal study with its chlamydia vaccine candidate. The study confirms that an adapted…
Eurocine Vaccines publishes half-year report for July-December 2020
Eurocine Vaccines AB (“Eurocine Vaccines”) hereby publishes an interim report for the first half year of 2020. Below is a summary of the report. The…
Eurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidate
Eurocine Vaccines AB (“Eurocine Vaccines” or the “Company”) has today selected Biovian Oy, Turku, Finland, (“Biovian”) as the contract developer for the Company's vaccine candidate…
Eurocine Vaccines advances the development of commercial manufacturing method and updates time plan
In connection with the procurement of contract manufacturer for the active protein in the chlamydia vaccine candidate, Eurocine Vaccines AB (“Eurocine Vaccines” or the “Company”)…
Eurocine Vaccines has signed an evaluation agreement to evaluate Endocine™ in the veterinary field
Eurocine Vaccines AB (“Eurocine Vaccines” or “the Company”) announces today that the Company has signed an evaluation agreement with a distinguished regional company, for an…
Eurocine Vaccines´ Interim report July-September 2020
Eurocine Vaccines AB (”Eurocine Vaccines”) herby publishes the interim report for the first quarter of 2020/2021. Below is a brief summary of the interim report.…
Eurocine Vaccines AB is moved to the Observation List
Following today’s press release from Spotlight, the company’s share will be moved to Spotlight’s Observation List. Information about the share: Shortname: EUCI ISIN-code: SE0001839069 Orderbook-ID:Read…
11/19 – Eurocine Vaccines AB is moved to the Observation List
Following today’s press release from Spotlight, the company’s share will be moved to Spotlight’s Observation List. Information about the share: Shortname: EUCI ISIN-code: SE0001839069 Orderbook-ID:Read…
Eurocine Vaccines´ nasal influenza vaccine candidate Immunose™ FLU showed good safety in older adults
Eurocine Vaccines today announced good safety and tolerability in older adults, in the second clinical phase I/II study including their quadrivalent influenza vaccine candidate. Immunose™Read…